The Interaction of Porcine Dihydropyrimidine Dehydrogenase with the Chemotherapy Sensitizer: 5-Ethynyluracil.
Sign Up to like & getrecommendations! Published in 2021 at "Biochemistry"
DOI: 10.1021/acs.biochem.1c00096
Abstract: Dihydropyrimidine dehydrogenase (DPD) is a complex enzyme that reduces the 5,6-vinylic bond of pyrimidines, uracil, and thymine. 5-Fluorouracil (5FU) is also a substrate for DPD and a common chemotherapeutic agent used to treat numerous cancers.… read more here.
Keywords: interaction porcine; dihydropyrimidine dehydrogenase; dehydrogenase; cross linking ... See more keywords
Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15536
Abstract: Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre‐analytical recommendations for determining U and dihydrouracil… read more here.
Keywords: dihydropyrimidine dehydrogenase; impact pre; pre analytical; quantitative impact ... See more keywords
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
Sign Up to like & getrecommendations! Published in 2020 at "Oncology Research and Treatment"
DOI: 10.1159/000510258
Abstract: Background: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2–1.0%.… read more here.
Keywords: dihydropyrimidine dehydrogenase; treatment; consensus; oncology ... See more keywords
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155217732141
Abstract: 5-fluorouracil and capecitabine are chemotherapeutic agents commonly used to treat solid malignancies. Increased susceptibility to 5-fluorouracil or capecitabine, caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, or other genetic mutations in the enzymes that metabolize 5-fluorouracil… read more here.
Keywords: dihydropyrimidine dehydrogenase; dihydropyrimidine; uridine triacetate; patient homozygous ... See more keywords
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience
Sign Up to like & getrecommendations! Published in 2018 at "Dose-Response"
DOI: 10.1177/1559325818803042
Abstract: Background: Severe toxicity is experienced by a substantial minority of patients receiving fluoropyrimidine-based chemotherapy, with approximately 20% of these severe toxicities attributable to polymorphisms in the DPYD gene. The DPYD codes for the enzyme dihydropyrimidine… read more here.
Keywords: chemotherapy; dpyd; dihydropyrimidine dehydrogenase; colorectal cancer ... See more keywords
Allele frequencies of two dihydropyrimidine dehydrogenase (DPYD) risk variants, c.1905+1G>A (*2A) and c.2846A>T (D949V), in a direct-to-consumer genetic database.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.2
Abstract: 2Background: Pharmacogenetic (PGt) testing holds great potential for supporting clinical decision making and optimizing medication outcomes for cancer patients. Genetic variants in the DPYD gene ar... read more here.
Keywords: two dihydropyrimidine; dihydropyrimidine dehydrogenase; frequencies two; allele frequencies ... See more keywords
Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine"
DOI: 10.2169/internalmedicine.8636-21
Abstract: Dihydropyrimidine dehydrogenase (DPD) deficiency induces severe adverse events in patients receiving fluoropyrimidines. We encountered a 64-year-old DPD-deficient man with a severe capecitabine-related gastrointestinal disorder. He received capecitabine-containing chemotherapy after rectal cancer resection. During the first… read more here.
Keywords: dihydropyrimidine dehydrogenase; gastrointestinal disorder; capecitabine; deficiency ... See more keywords
Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
Sign Up to like & getrecommendations! Published in 2017 at "Current pharmaceutical design"
DOI: 10.2174/1381612823666170125155530
Abstract: BACKGROUND Fluoropyrimidines are widely used in the treatment of solid tumors and remain the backbone of many combination chemotherapy regimens. Despite their clinical benefit, they are associated with frequent gastrointestinal and hematological toxicities, which often… read more here.
Keywords: science implementation; dihydropyrimidine dehydrogenase; treatment; metabolism science ... See more keywords
Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
Sign Up to like & getrecommendations! Published in 2022 at "ecancermedicalscience"
DOI: 10.3332/ecancer.2022.1344
Abstract: Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially… read more here.
Keywords: dihydropyrimidine dehydrogenase; dehydrogenase; polymorphisms knocking; knocking door ... See more keywords